Xeris Biopharma Holdings Q4 GAAP EPS $(0.10), Inline, Sales $44.39M Beat $43.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma Holdings (NASDAQ:XERS) reported Q4 GAAP EPS of $(0.10), meeting analyst consensus estimates, with sales of $44.39M surpassing the $43.55M estimate, marking a 33.93% increase from the previous year.
March 06, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma Holdings reported Q4 GAAP EPS of $(0.10), in line with estimates, and sales of $44.39M, beating estimates by 1.93% and showing a 33.93% increase YOY.
Meeting EPS estimates and exceeding sales forecasts, especially with a significant year-over-year increase, is likely to be viewed positively by investors. This performance indicates solid revenue growth, which could lead to a positive short-term impact on XERS's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100